Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

160.45 -2.10 (-1.29%)
Official Closing Price Updated: 4:10 PM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,803,501
Open 162.14
Bid (Size) 160.07 (1)
Ask (Size) 161.00 (9)
Prev. Close 162.55
Today's Range 159.87 - 162.90
52wk Range 130.96 - 182.89
Shares Outstanding N/A
Dividend Yield 3.69%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
AbbVie Tracking for New Highs in 2024
Future Dividend King AbbVie is tracking for new highs as the shift away from Humira-based business gains momentum with new treatments and acquisitions. 
Via MarketBeat
Topics Earnings
Exposures Financial

Performance

YTD
+0.39%
+0.39%
1 Month
-5.51%
-5.51%
3 Month
-7.41%
-7.41%
6 Month
+12.87%
+12.87%
1 Year
+8.82%
+8.82%

More News

Read More
3 Biotech Stocks to Double Your Money in the Next 24 Months
Via InvestorPlace
3 Reasons to Buy AbbVie Stock on the Dip
Via The Motley Fool
MarketBeat Week in Review – 4/29 - 5/3
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
Via Benzinga
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Via Benzinga
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
Via InvestorPlace
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
Via MarketBeat
Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing
Via InvestorPlace
Topics Economy
Exposures Interest Rates
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
Via Investor's Business Daily
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Better Dividend Stock: AbbVie or Johnson & Johnson?
Via The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Via The Motley Fool
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Via Benzinga
Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?
Via Benzinga
Topics Economy
Exposures Interest Rates
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
Via Benzinga
AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title
Via Investor's Business Daily
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
Via Benzinga
Topics Economy
Exposures Interest Rates
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Via InvestorPlace
Dividend Growth Stars: 7 Stocks With 10-Year Double-Digit Rate Hikes
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.